DUBLIN – Enterome SA is getting $50 million up front plus up to $640 million more in clinical development, regulatory and commercial milestones in a global licensing and co-development deal with Takeda Pharmaceutical Co. Ltd., under which the two companies will jointly take forward its lead drug, EB-8018, which is currently in development for Crohn's disease. Osaka, Japan-based Takeda has also committed to invest $15 million in Paris-based Enterome at a future date.